Isofol reaches new phase Ib/II milestones in Europe – prepares Japanese study with Solasia
13 november, 08:04
13 november, 08:04
Isofol Medical continued to make solid progress in the third quarter. The ongoing phase Ib/II study of arfolitixorin is advancing according to plan, and the company has now received clearance to escalate to the next dose level following positive safety findings. Meanwhile, partner Solasia Pharma has become one of Isofol’s largest shareholders and is investing SEK 140 million to fund clinical development in Japan. BioStock spoke with CEO Petter Segelman Lindqvist to learn more.
Read the full article at biostock.se:
https://biostock.se/en/2025/11/isofol-nar-nya-milstolpar-i-fas-ib-ii-studien-i-europa-forbereder-japansk-studie-med-solasia/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
13 november, 08:04
Isofol Medical continued to make solid progress in the third quarter. The ongoing phase Ib/II study of arfolitixorin is advancing according to plan, and the company has now received clearance to escalate to the next dose level following positive safety findings. Meanwhile, partner Solasia Pharma has become one of Isofol’s largest shareholders and is investing SEK 140 million to fund clinical development in Japan. BioStock spoke with CEO Petter Segelman Lindqvist to learn more.
Read the full article at biostock.se:
https://biostock.se/en/2025/11/isofol-nar-nya-milstolpar-i-fas-ib-ii-studien-i-europa-forbereder-japansk-studie-med-solasia/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
17 december, 15:42
Året 2025
Analys
Analys
Fonder
Privatekonomi

Utredningen mot Intellego

17 december, 15:42
Året 2025
Analys
Analys
Fonder
Privatekonomi

Utredningen mot Intellego

Boliden
Igår, 17:42
Nytt indexrekord avslutade året
Saab
Igår, 16:42
Saab får fransk stororder
OMX Stockholm 30
1 DAG %
Senast
2 882,97